ZNF143 Expression is Associated with COPD and Tumor Microenvironment in Non-Small Cell Lung Cancer

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. doi:10.3322/caac.21590
   PubMed Web of Science ®Google Scholar
• Faruki H, Mayhew GM, Serody JS, Hayes DN, Perou CM, Lai-Goldman M. Lung adenocarcinoma and squamous cell carcinoma gene expression subtypes demonstrate significant differences in tumor immune landscape. J Thorac Oncol. 2017;12(6):943–953. doi:10.1016/j.jtho.2017.03.010
   PubMed Web of Science ®Google Scholar
• Malhotra J, Malvezzi M, Negri E, La Vecchia C, Boffetta P. Risk factors for lung cancer worldwide. Eur Respir J. 2016;48(3):889–902. doi:10.1183/13993003.00359-2016
   PubMed Web of Science ®Google Scholar
• Liu C, Zhou X, Zeng H, Wu D, Liu L. HILPDA is a prognostic biomarker and correlates with macrophage infiltration in pan-cancer. Front Oncol. 2021;11:597860. doi:10.3389/fonc.2021.597860
   PubMed Web of Science ®Google Scholar
• Treekitkarnmongkol W, Hassane M, Sinjab A, et al. Augmented Lipocalin-2 is associated with chronic obstructive pulmonary disease and counteracts lung adenocarcinoma development. Am J Resp Crit Care. 2021;203(1):90–101. doi:10.1164/rccm.202004-1079OC
   PubMed Web of Science ®Google Scholar
• Liu C, Chen Z, Chen K, et al. Lipopolysaccharide-mediated chronic inflammation promotes tobacco carcinogen-induced lung cancer and determines the efficacy of immunotherapy. Cancer Res. 2020:canres.1994.2020. doi:10.1158/0008-5472.CAN-20-1994
   Web of Science ®Google Scholar
• Eapen MS, Hansbro PM, Larsson Callerfelt A, et al. Chronic obstructive pulmonary disease and lung cancer: underlying pathophysiology and new therapeutic modalities. Drugs. 2018;78(16):1717–1740. doi:10.1007/s40265-018-1001-8
   PubMed Web of Science ®Google Scholar
• Qin J, Li G, Zhou J. Characteristics of elderly patients with COPD and newly diagnosed lung cancer, and factors associated with treatment decision. Int J Chron Obstruct Pulmon Dis. 2016;11:1515–1520. doi:10.2147/COPD.S104670
   PubMed Web of Science ®Google Scholar
• Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer. New Engl J Med. 2015;373(2):123–135. doi:10.1056/NEJMoa1504627
   PubMed Web of Science ®Google Scholar
• Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. New Engl J Med. 2015;373(17):1627–1639. doi:10.1056/NEJMoa1507643
   PubMed Web of Science ®Google Scholar
• Lievense LA, Sterman DH, Cornelissen R, Aerts JG. Checkpoint blockade in lung cancer and mesothelioma. Am J Resp Crit Care. 2017;196(3):274–282. doi:10.1164/rccm.201608-1755CI
   PubMed Web of Science ®Google Scholar
• Biton J, Ouakrim H, Dechartres A, et al. Impaired tumor-infiltrating T cells in patients with chronic obstructive pulmonary disease impact lung cancer response to PD-1 blockade. Am J Resp Crit Care. 2018;198(7):928–940. doi:10.1164/rccm.201706-1110OC
   PubMed Web of Science ®Google Scholar
• Mark NM, Kargl J, Busch SE, et al. Chronic obstructive pulmonary disease alters immune cell composition and immune checkpoint inhibitor efficacy in non–small cell lung cancer. Am J Resp Crit Care. 2018;197(3):325–336. doi:10.1164/rccm.201704-0795OC
   PubMed Web of Science ®Google Scholar
• Zhang L, Chen J, Yang H, et al. Multiple microarray analyses identify key genes associated with the development of non-small cell lung cancer from chronic obstructive pulmonary disease. J Cancer. 2021;12(4):996–1010. doi:10.7150/jca.51264
   PubMed Web of Science ®Google Scholar
• Miao T, Du L, Xiao W, Mao B, Wang Y, Fu J. Identification of survival-associated gene signature in lung cancer coexisting with COPD. Front Oncol. 2021;11. doi:10.3389/fonc.2021.600243
   Web of Science ®Google Scholar
• Li CY, Cai J, Tsai JJP, Wang CCN. Identification of hub genes associated with development of head and neck squamous cell carcinoma by integrated bioinformatics analysis. Front Oncol. 2020;10. doi:10.3389/fonc.2020.00681
   Web of Science ®Google Scholar
• Can T. Introduction to bioinformatics. Methods Mol Biol. 2014;1107:51–71. doi:10.1007/978-1-62703-748-8_4
   PubMedGoogle Scholar
• San Segundo-Val I, Sanz-Lozano CS. Introduction to the Gene Expression Analysis. New York, NY: Springer New York; 2016:29–43.
   Google Scholar
• Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinform. 2008;9(1):559. doi:10.1186/1471-2105-9-559
   PubMed Web of Science ®Google Scholar
• Zhou J, Guo H, Liu L, et al. Construction of co‐expression modules related to survival by WGCNA and identification of potential prognostic biomarkers in glioblastoma. J Cell Mol Med. 2021;25(3):1633–1644. doi:10.1111/jcmm.16264
   PubMed Web of Science ®Google Scholar
• Tian W, Yang X, Yang H, Zhou B. GINS2 functions as a key gene in lung adenocarcinoma by WGCNA Co-Expression network analysis. Onco Targets Ther. 2020;13:6735–6746. doi:10.2147/OTT.S255251
   PubMed Web of Science ®Google Scholar
• López NC, García-Ordás MT, Vitelli-Storelli F, Fernández-Navarro P, Palazuelos C, Alaiz-Rodríguez R. Evaluation of feature selection techniques for breast cancer risk prediction. Int J Env Res Pub He. 2021;18(20):10670. doi:10.3390/ijerph182010670
   PubMed Web of Science ®Google Scholar
• Morrow JD, Zhou X, Lao T, et al. Functional interactors of three genome-wide association study genes are differentially expressed in severe chronic obstructive pulmonary disease lung tissue. Sci Rep-Uk. 2017;7(1). doi:10.1038/srep44232
   Web of Science ®Google Scholar
• Ezzie ME, Crawford M, Cho J, et al. Gene expression networks in COPD: microRNA and mRNA regulation. Thorax. 2012;67(2):122–131. doi:10.1136/thoraxjnl-2011-200089
   PubMed Web of Science ®Google Scholar
• Feng Z, Zhang J, Zheng Y, Wang Q, Min X, Tian T. Elevated expression of ASF1B correlates with poor prognosis in human lung adenocarcinoma. Pers Med. 2021;18(2):115–127. doi:10.2217/pme-2020-0112
   PubMed Web of Science ®Google Scholar
• Schabath MB, Welsh EA, Fulp WJ, et al. Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma. Oncogene. 2016;35(24):3209–3216. doi:10.1038/onc.2015.375
   PubMed Web of Science ®Google Scholar
• Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401–404. doi:10.1158/2159-8290.CD-12-0095
   PubMed Web of Science ®Google Scholar
• Feng Z, Zhang J, Zheng Y, Liu J, Duan T, Tian T. Overexpression of abnormal spindle-like microcephaly-associated (ASPM) increases tumor aggressiveness and predicts poor outcome in patients with lung adenocarcinoma. Transl Cancer Res. 2021;10(2):983–997. doi:10.21037/tcr-20-2570
   PubMed Web of Science ®Google Scholar
• Zhou R, Zhang J, Zeng D, et al. Immune cell infiltration as a biomarker for the diagnosis and prognosis of stage I–III colon cancer. Cancer Immunol Immunother. 2019;68(3):433–442. doi:10.1007/s00262-018-2289-7
   PubMed Web of Science ®Google Scholar
• Jiang P, Gu S, Pan D, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24(10):1550–1558. doi:10.1038/s41591-018-0136-1
   PubMed Web of Science ®Google Scholar
• Wang X, Kong C, Xu W, et al. Decoding tumor mutation burden and driver mutations in early stage lung adenocarcinoma using CT‐based radiomics signature. Thorac Cancer. 2019;10(10):1904–1912. doi:10.1111/1759-7714.13163
   PubMed Web of Science ®Google Scholar
• Chalmers ZR, Connelly CF, Fabrizio D, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9(1):34. doi:10.1186/s13073-017-0424-2
   PubMed Web of Science ®Google Scholar
• Izumi H, Wakasugi T, Shimajiri S, et al. Role of ZNF143 in tumor growth through transcriptional regulation of DNA replication and cell-cycle-associated genes. Cancer Sci. 2010;101(12):2538–2545. doi:10.1111/j.1349-7006.2010.01725.x
   PubMed Web of Science ®Google Scholar
• Paek AR, Mun JY, Hong K, Lee J, Hong DW, You HJ. Zinc finger protein 143 expression is closely related to tumor malignancy via regulating cell motility in breast cancer. Bmb Rep. 2017;50(12):621–627. doi:10.5483/BMBRep.2017.50.12.177
   PubMed Web of Science ®Google Scholar
• Chen YR, Leung JM, Sin DD. A systematic review of diagnostic biomarkers of COPD exacerbation. PLoS One. 2016;11(7):e0158843. doi:10.1371/journal.pone.0158843
   PubMed Web of Science ®Google Scholar
• Sin DD, Hollander Z, DeMarco ML, McManus BM, Ng RT. Biomarker development for chronic obstructive pulmonary disease. from discovery to clinical implementation. Am J Resp Crit Care. 2015;192(10):1162–1170. doi:10.1164/rccm.201505-0871PP
   PubMed Web of Science ®Google Scholar
• Kawatsu Y, Kitada S, Uramoto H, et al. The combination of strong expression of ZNF143 and high MIB-1 labelling index independently predicts shorter disease-specific survival in lung adenocarcinoma. Brit J Cancer. 2014;110(10):2583–2592. doi:10.1038/bjc.2014.202
   PubMed Web of Science ®Google Scholar
• Ye B, Yang G, Li Y, Zhang C, Wang Q, Yu G. ZNF143 in chromatin looping and gene regulation. Front Genet. 2020;11. doi:10.3389/fgene.2020.00338
   Web of Science ®Google Scholar
• Haibara H, Yamazaki R, Nishiyama Y, et al. YPC‐21661 and YPC‐22026, novel small molecules, inhibit ZNF143 activity in vitro and in vivo. Cancer Sci. 2017;108(5):1042–1048. doi:10.1111/cas.13199
   PubMed Web of Science ®Google Scholar
• Young RP, Hopkins RJ, Christmas T, Black PN, Metcalf P, Gamble GD. COPD prevalence is increased in lung cancer, independent of age, sex and smoking history. Eur Respir J. 2009;34(2):380–386. doi:10.1183/09031936.00144208
   PubMed Web of Science ®Google Scholar
• Chen Y, Zhang Y, Lv J, et al. Genomic analysis of tumor microenvironment immune types across 14 solid cancer types: immunotherapeutic implications. Theranostics. 2017;7(14):3585–3594. doi:10.7150/thno.21471
   PubMed Web of Science ®Google Scholar
• Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348(6230):56–61. doi:10.1126/science.aaa8172
   PubMed Web of Science ®Google Scholar
• Trujillo JA, Sweis RF, Bao R, Luke JJ. T cell–inflamed versus Non-T cell–inflamed tumors: a conceptual framework for cancer immunotherapy drug development and combination therapy selection. Cancer Immunol Res. 2018;6(9):990–1000. doi:10.1158/2326-6066.CIR-18-0277
   PubMed Web of Science ®Google Scholar
• Takayama Y, Nakamura T, Fukushiro Y, Mishima S, Masuda K, Shoda H. Coexistence of emphysema with non-small-cell lung cancer predicts the therapeutic efficacy of immune checkpoint inhibitors. In Vivo (Brooklyn). 2021;35(1):467–474. doi:10.21873/invivo.12280
   Web of Science ®Google Scholar
• Kadara H, Scheet P, Wistuba II, Spira AE. Early events in the molecular pathogenesis of lung cancer. Cancer Prev Res. 2016;9(7):518–527. doi:10.1158/1940-6207.CAPR-15-0400
   PubMed Web of Science ®Google Scholar
• Kim A, Lim SM, Kim J, Seo J. Integrative genomic and transcriptomic analyses of tumor suppressor genes and their role on tumor microenvironment and immunity in lung squamous cell carcinoma. Front Immunol. 2021;12. doi:10.3389/fimmu.2021.598671
   Web of Science ®Google Scholar
• Toyokawa G, Takada K, Okamoto T, et al. High frequency of programmed death-ligand 1 expression in emphysematous bullae-associated lung adenocarcinomas. Clin Lung Cancer. 2017;18(5):504–511. doi:10.1016/j.cllc.2016.11.011
   PubMed Web of Science ®Google Scholar